Windhover Information's Audio Conference: ``Gardasil, Menactra and the Vaccine Boom: The Reasons Behind the Resurgence in Commercially Successful Vaccines and the Threats Ahead''.

NORWALK, Conn. -- Major Players, Analysts to Reveal Secrets to Success in This Volatile Field; July 17, 2006

Windhover Information's The RPM Report: Regulation - Policy - Market Access is joining with prominent experts on public-private sector vaccine issues to produce an audioconference on the hot new landscape in the vaccine market.

Dack Dalrymple, Principal, Dalrymple & Associates, and Clement Lewin, Acambis Vice President of Biodefense and Policy, will be joined by The RPM Report Senior Editor Kate Rawson and Editor-in-Chief Cole Werble in a discussion of the events that have made the vaccine market so attractive, and what kind of long-term potential the market holds.

Windhover is currently accepting registration for this upcoming event at www.windhover.com/audioconference, or by contacting Alexandria Riley at [e-mail], or at [phone] x113.

Industry experts to share valuable strategic insights

Dalrymple has spent more than 25 years representing a broad spectrum of vaccine companies in their search for government support for both the development of new products and rapid commercial acceptance. Dalrymple's knowledge of vaccine issues stretches back to the swine flu vaccination program in 1976. As a Congressional health subcommittee counsel, he participated in the effort to craft liability exposure protections for manufacturers in that program and has been involved in the many subsequent liability protections for vaccines.

Lewin has extensive experience in the vaccine business and has been involved in two recent efforts by new participants to carve out positions in the field. He was VP government affairs and immunization policy for Chiron until 2005, then moving to VP-government affairs and strategy at Acambis. He recently has assumed responsibility for biodefense and policy at Acambis. His knowledge of the industry gives him an unusual perspective on the attractions and barriers to entry in the field. He serves as the liaison for BIO to the important Advisory Committee on Immunization Practices of the Centers for Disease Control.

Lewin and Dalrymple will discuss the involvement of biopharma giants Merck, Sanofi-Aventis, GlaxoSmithKline, Novartis and Wyeth in the emerging vaccine market -- despite gloomy headlines about shortages of flu vaccine and older, single-component products that masked the potential of the market -- along with issues such as what these early players saw that made the market attractive, and what risks lie ahead for them and for newcomers to the field.

Rawson, who has been writing extensively on the development of Merck's Gardasil and the strategy of the second vaccine aimed at the human papilloma virus market, GlaxoSmithKline's Cervarix, will provide a case study examination of how Merck has navigated the complicated scientific/political nexus to get the first anti-cancer vaccine to market and gain a head-start in a $1 billion-plus category. She will also discuss whether there is room for Cervarix in the HPV vaccine category, and how GSK will be positioning its vaccine against the market leader, Gardasil.

Werble is the co-author of a market examination of the vaccine field for the National Health Policy Forum. He will explain how government regulation and added financial risks can add to the strength of proprietary positions for companies that succeed in the field, and how the legacy of Clinton health care reform has come to create a very appealing commercial landscape for the right types of vaccines.

Key issues to be covered at this groundbreaking conference include:

--How has the government's vaccine entitlement program built a profitable model for a resurgence in vaccine R&D? How long can it last?

--Why is the flu vaccine market now appearing more attractive than in years past? How are manufacturers taking advantage?

--How will Sanofi-Aventis' meningococcal vaccine Menactra remain viable after its initial launch?

--What are the future risks to vaccine marketing? How long will the government continue to accept new vaccines at premium prices?

--What co-ventures and deals have promising prospects?

--Can Merck win approval of Gardasil as a vaccine for boys as well as girls?

--Will Merck face a social backlash from the proponents of sexual abstinence when Gardasil reaches the market?

--Is there room for a GlaxoSmithKline product in the category? How will Cervarix be positioned against Gardasil?

The conference is aimed at senior executives at vaccine and biopharmaceutical firms, venture capitalists and angel investor groups, investment bankers, buy-side and sell-side researchers, and government and regulatory affairs executives.

Participants receive toll-free telephone access (U.S. only) to the conference, along with a PDF of the presentation ahead of time and access to a web site for viewing the presenter's slides as they speak to them. Participants will be able to ask questions of the speakers by phone or email. Also available is a digital recording of the entire event including all slides, sent approximately one week after the conference.

Windhover offers a variety of audio conferences as a less expensive, more flexible alternative to its premier conference events held around the world. With no travel required, entire teams can take part in Windhover's renowned audio conferences for very little cost and trouble. For more information on Windhover's audio conferences, visit the website at www.windhover.com/audioconference, email [e-mail], or call [phone] x113.

About Windhover Information

Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see www.windhover.com.